These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23404615)

  • 1. The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results.
    Silverman S; Miller P; Sebba A; Weitz M; Wan X; Alam J; Masica D; Taylor KA; Ruff VA; Krohn K
    Osteoporos Int; 2013 Aug; 24(8):2309-17. PubMed ID: 23404615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study.
    Beall DP; Feldman RG; Gordon ML; Gruber BL; Lane JM; Valenzuela G; Yim D; Alam J; Krege JH; Krohn K
    Osteoporos Int; 2016 Mar; 27(3):1191-1198. PubMed ID: 26556737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender differences for initiating teriparatide therapy: baseline data from the Direct Assessment of Nonvertebral Fracture in the Community Experience (DANCE) study.
    Wong M; Wan X; Ruff V; Krohn K; Taylor K
    Osteoporos Int; 2012 Apr; 23(4):1445-52. PubMed ID: 21769662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
    Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
    Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
    Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
    Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.
    Reginster JY; Kaufman JM; Goemaere S; Devogelaer JP; Benhamou CL; Felsenberg D; Diaz-Curiel M; Brandi ML; Badurski J; Wark J; Balogh A; Bruyère O; Roux C
    Osteoporos Int; 2012 Mar; 23(3):1115-22. PubMed ID: 22124575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients.
    Ebina K; Hashimoto J; Shi K; Kashii M; Hirao M; Yoshikawa H
    Osteoporos Int; 2014 Dec; 25(12):2755-65. PubMed ID: 25082556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
    Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
    Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.
    Silverman SL; Siris E; Kendler DL; Belazi D; Brown JP; Gold DT; Lewiecki EM; Papaioannou A; Simonelli C; Ferreira I; Balasubramanian A; Dakin P; Ho P; Siddhanti S; Stolshek B; Recknor C
    Osteoporos Int; 2015 Jan; 26(1):361-72. PubMed ID: 25236877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoporotic fractures and associated hospitalizations among patients treated with teriparatide compared to a matched cohort of patients not treated with teriparatide.
    Boytsov N; Zhang X; Sugihara T; Taylor K; Swindle R
    Curr Med Res Opin; 2015; 31(9):1665-75. PubMed ID: 26121328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teriparatide treatment of severe osteoporosis reduces the risk of vertebral fractures compared with standard care in routine clinical practice.
    Oswald AJ; Berg J; Milne G; Ralston SH
    Calcif Tissue Int; 2014 Feb; 94(2):176-82. PubMed ID: 24026567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.
    Anastasilakis AD; Polyzos SA; Makras P; Gkiomisi A; Bisbinas I; Katsarou A; Filippaios A; Mantzoros CS
    Osteoporos Int; 2014 May; 25(5):1633-42. PubMed ID: 24599275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis.
    Hagino H; Narita R; Yokoyama Y; Watanabe M; Tomomitsu M
    Osteoporos Int; 2019 Oct; 30(10):2027-2037. PubMed ID: 31243480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Effects of Teriparatide Followed by Antiresorptive Therapy on Clinical Outcomes in Patients with Severe Spinal Osteoporosis.
    Oswald AJ; Berg K; Ralston SH; Riches PL
    Calcif Tissue Int; 2019 Aug; 105(2):148-155. PubMed ID: 31115640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
    Cosman F; Nieves JW; Zion M; Garrett P; Neubort S; Dempster D; Lindsay R
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study.
    Nishikawa A; Yoshiki F; Taketsuna M; Kajimoto K; Enomoto H
    Clin Interv Aging; 2016; 11():1653-1659. PubMed ID: 27895472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
    Stepan JJ; Burr DB; Li J; Ma YL; Petto H; Sipos A; Dobnig H; Fahrleitner-Pammer A; Michalská D; Pavo I
    Osteoporos Int; 2010 Dec; 21(12):2027-36. PubMed ID: 20135094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.